A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma

Study Purpose

This is a multicenter, multi-country, open-label, Phase 1b/2a dose-escalation study consisting of two parts: dose escalation (Part 1) for CC-220 monotherapy, CC-220 in combination with DEX, CC-220 in combination with DEX and DARA, CC-220 in combination with DEX and BTZ and CC-220 in combination with DEX and CFZ; and the expansion of the RP2D (Part 2) for CC-220 in combination with DEX for Relapsed Refractory Multiple Myeloma and CC-220 in combination with DEX and BTZ for Newly Diagnosed Multiple Myeloma.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2.
  • - Relapsed and refractory multiple myeloma (RRMM) participants must have documented disease progression on or within 60 days from the last dose of their last myeloma therapy.
  • - Newly diagnosed multiple myeloma (NDMM) participants must have documented diagnosis with previously untreated symptomatic multiple myeloma (MM) - Participants in Cohorts J1 and K are those for whom autologous stem cell transplantation is not planned for initial therapy or are not considered by the investigator as eligible for high-dose chemotherapy and autologous stem cell transplantation.

Exclusion Criteria:

  • - Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study.
  • - Nonsecretory multiple myeloma.
  • - Prior history of malignancies, other than MM, unless the participant has been free of the disease for ≥ 5 years.
Other protocol-defined inclusion/exclusion criteria apply

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT02773030
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 1/Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Celgene
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Bristol-Myers Squibb
Principal Investigator Affiliation Bristol-Myers Squibb
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries Australia, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Spain, United Kingdom, United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Multiple Myeloma
Study Website: View Trial Website
Additional Details

Subjects assigned to CC-220 monotherapy, who develop progressive disease (PD) will have the option to receive DEX in addition to CC-220 after consultation with the Medical Monitor. The dose of CC-220 will not be higher than the dose of CC-220 used in combination with dexamethasone in Cohort B that has been determined to be safe. Progressive disease must be confirmed in accordance with international myeloma working group (IMWG) criteria. The starting dose of DEX will be 40 mg for subjects who are ≤75 years of age and 20 mg for subjects who are >75 years of age, given once weekly. This treatment will continue until PD, unacceptable toxicity or the subject withdraws consent. For Cohorts A and B, the starting dose level of CC-220, dose level 1, is 0.3 mg. A dose level -1, of 0.15 mg, may also be evaluated if the starting dose level of 0.3 mg for 21 days of a 28-day cycle is not tolerated. For Cohorts E and F, the starting dose level of CC-220, dose level 1, is one dose level below the maximum dose for Cohort B that has been determined to be safe by the dose escalation committee (DEC) at the start of enrollment for both cohorts. For Cohort E in addition to CC-220 and DEX, daratumumab will be administered intravenously (IV) at a 16mg/kg dose. For Cohort F in addition to CC-220 and DEX, bortezomib will be administered subcutaneous (SC) at a 1.3mg/m2 dose. All subjects with a minimal response (MR) or better who discontinue study treatment in Part 1 or Part 2 of the study for a reason other than PD or withdrawal of consent from the study will be followed for response assessment every 28 days (every 21 days for Cohort F) until PD. The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements. The initiation of Part 2 will begin when the RP2D is established in Part 1 in either Cohort A or Cohort B. Either cohort may begin once the RP2D is determined for each cohort independently during Part 1. All expansion decisions will be determined by the DEC after review of all safety, PK, biomarker and preliminary efficacy data, as applicable. During Part 2, the Independent Expert Reviewer will review safety data and any other data deemed relevant so that subject safety is ensured.

Arms & Interventions

Arms

Experimental: Cohort A: CC-220 Monotherapy - Part 1

Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle

Experimental: Cohort B: CC-220 in combination with Dexamethasone (DEX) - Part 1

Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle. For subjects ≤ 75 years old, oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, DEX will be administered at 20 mg on Days 1, 8,15, and 22 of each 28-day cycle. Subjects who surpass the age of 75 years while on treatment may be switched to the 20 mg QD dosage based on the investigator's best judgment.

Experimental: Cohort D: CC-220 in combination with Dexamethasone - Part 2

Oral CC-220 at Recommended Phase 2 dose (RP2D) from Day 1-21 of each 28-day cycle Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle

Experimental: Cohort E: CC-220 with DEX and daratumumab (DARA) - Part 1

Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle. Oral DEX for subjects ≤ 75 years old at 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, oral DEX at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle. Intravenous DARA at dose 16mg/kg on Days 1, 8, 15, and 22 at cycle 1-2, Days 1, 15 at cycle 3-6, and Day 1 at cycle ≥7 of each 28-day cycle. Once the MTD and/or RP2D is determined in Cohort E (CC-220Dd), subjects will be enrolled at this dose level using SC DARA. Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle. Oral DEX for subjects ≤ 75 years old at 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, oral DEX at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle. Subcutaneous DARA at dose 1800 mg over 3 to 5 minutes on Days 1, 8, 15, and 22 at cycle 1-2, Days 1, 15 at cycle 3-6, and Day 1 at cycle ≥7 of each 28-day cycle.

Experimental: Cohort F: CC-220 with DEX and bortezomib - Part 1

Oral CC-220 at dose specified by cohort dose level from Day 1-14 of each 21-day cycle. Oral DEX for subjects ≤ 75 years old at 40 mg on Days 1, 8, and 15 of each 21-day cycle. For subjects >75 years old, oral DEX at 20 mg on Days 1, 8, and 15 of each 21-day cycle. Subcutaneous BTZ at dose 1.3 mg/m^2 on Days 1, 4, 8 and 11 at cycle 1-8, and Days 1, 8 at cycle ≥9 of each 21-day cycle.

Experimental: Cohort G1: CC-220 in combination with CFZ and DEX - Part 1

Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle Intravenous (IV) CFZ (Carfilzomib)administered at a starting dose of 20 mg/m2 on C1D1; and at a dose specified by cohort dose level thereafter on days 1, 8, 15 of each 28-day cycle Oral DEX (Dexamethasone) on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects ≤ 75 years old, the DEX dose will be 40 mg. For subjects > 75 years old, the DEX dose will be 20 mg

Experimental: Cohort G2 - CC-220 in combination with CFZ and DEX - Part 1

Oral CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle Intravenous (IV) CFZ administered at a starting dose of 20 mg/m2 on C1D1; and at a dose level specified by cohort dose level thereafter Days 1, 2, 8, 9, 15, 16 of each 28-day cycle Oral DEX on Days 1, 2, 8, 9, 15, 16, 22, 23 of each 28-day cycle. The DEX dose will be 20 mg

Experimental: Cohort I: CC-220 in combination with DEX in post BCMA RRMM - Part 2

Oral CC-220 at Recommended Phase 2 dose (RP2D) from Day 1-21 of each 28-day cycle Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, oral DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle.

Experimental: Cohort J1: CC-220 in combination with DEX and BTZ in NDMM - Part 2

Oral CC-220 at Recommended Phase 2 Dose from Day 1-14 of each 21-day cycle (Cycle 1 to 8) and from Day 1-21 of each 28-day cycle (Cycle 9 and above). Oral DEX at Cycles 1 to 8, 20 mg (≤ 75 years old) or 10 mg (> 75 years old) on Days 1, 2, 4, 5, 8, 9, 11 and 12 of each 21-day cycle and Cycles ≥ 9, 40 mg (≤ 75 years old) or 20 mg (> 75 years old) on Days 1, 8, 15, and 22 of each 28-day cycle. Subcutaneous BTZ at dose 1.3 mg/m2 on Days 1, 4, 8 and 11 at Cycle 1-8 of each 21-day cycle.

Experimental: Cohort J2: CC-220 in combination with DEX and BTZ in NDMM - Part 2

Oral CC-220 at Recommended Phase 2 Dose from Day 1-14 of each 21-day cycle. Oral DEX at 20 mg/day (≤ 75 years old) or 10 mg/day (> 75 years old) for Cycles 1 to 6 on Days 1, 2, 4, 5, 8, 9, 11 and 12 of a 21-day cycle. Subcutaneous BTZ at dose 1.3 mg/m2 on Days 1, 4, 8 and 11 at Cycle 1-6 of each 21-day cycle.

Experimental: Cohort K: CC-220 with DEX and DARA in NDMM and not autologous stem cell transplant eligible

Part 2

Experimental: Cohort C: CC-220 Monotherapy in RRMM

Part 2

Interventions

Drug: - CC-220

CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle

Drug: - Dexamethasone

Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, oral DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle

Drug: - Daratumumab

Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects >75 years old, oral DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle

Drug: - Bortezomib

Bortezomib 1.3 mg/m^2 on Days 1, 4, 8 and 11 at cycle 1-8, and Days 1, 8 at cycle ≥9 of each 21-day cycle

Drug: - Carfilzomib

Intravenous (IV) CFZ administered at a starting dose of 20 mg/m2 on C1D1 and C1D2; and at a dose level specified by cohort dose level thereafter Days 1, 2, 8, 9, 15, 16 of each 28-day cycle

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Mayo Clinic, Scottsdale, Arizona

Status

Recruiting

Address

Mayo Clinic

Scottsdale, Arizona, 85259

Site Contact

Peter Bergsagel, Site 102

Clinical.Trials@bms.com

480-342-4800

The University of Arizona Cancer Center, Tucson, Arizona

Status

Withdrawn

Address

The University of Arizona Cancer Center

Tucson, Arizona, 85719

Local Institution - 107, Little Rock, Arkansas

Status

Completed

Address

Local Institution - 107

Little Rock, Arkansas, 72205

Atlanta, Georgia

Status

Recruiting

Address

Winship Cancer Institute of Emory University

Atlanta, Georgia, 30322

Site Contact

Sagar Lonial, Site 101

Clinical.Trials@bms.com

404-778-1900

Chicago, Illinois

Status

Recruiting

Address

Robert H Lurie Comprehensive Cancer Center NW Univ

Chicago, Illinois, 60611

Site Contact

Seema Singhal, Site 120

Clinical.Trials@bms.com

312-695-4159

Maywood, Illinois

Status

Withdrawn

Address

Loyola University Medical Center LUMC - Cardinal Bernardin Cancer Center CBCC

Maywood, Illinois, 60153

Fairway, Kansas

Status

Recruiting

Address

The University of Kansas - Clinical Research Center

Fairway, Kansas, 66205

Site Contact

Al-Ola Abdallah, Site 113

Clinical.Trials@bms.com

913-588-6078

University of Maryland School of Med, Baltimore, Maryland

Status

Recruiting

Address

University of Maryland School of Med

Baltimore, Maryland, 21201

Site Contact

Ashraf Badros, Site 106

Clinical.Trials@bms.com

410-328-1230

Saint Agnes Hospital, Baltimore, Maryland

Status

Withdrawn

Address

Saint Agnes Hospital

Baltimore, Maryland, 21229

Beth Israel Deaconess Medical Center, Boston, Massachusetts

Status

Recruiting

Address

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02115

Site Contact

Jacalyn Rosenblatt, Site 114

Clinical.Trials@bms.com

617-667-9920

Massachusetts General Hospital, Boston, Massachusetts

Status

Recruiting

Address

Massachusetts General Hospital

Boston, Massachusetts, 02117

Site Contact

Andrew Branagan, Site 115

Clinical.Trials@bms.com

617-724-4000

Boston, Massachusetts

Status

Recruiting

Address

Dana-Farber/Mass General Brigham Cancer Care, Inc

Boston, Massachusetts, 02215

Site Contact

Paul Richardson, Site 110

Clinical.Trials@bms.com

617-632-6624

Ann Arbor, Michigan

Status

Recruiting

Address

University Of Michigan Comprehensive Cancer Center

Ann Arbor, Michigan, 48109

Site Contact

Erica Campagnaro, Site 104

Clinical.Trials@bms.com

216-368-1176

Karmanos Cancer Institute, Detroit, Michigan

Status

Recruiting

Address

Karmanos Cancer Institute

Detroit, Michigan, 48201

Site Contact

Jeffrey Zonder, Site 103

Clinical.Trials@bms.com

313-576-8730

Grand Island, Nebraska

Status

Recruiting

Address

"Grand Island"- Oncology Hematology West, PC dba Nebraska Cancer Specialist

Grand Island, Nebraska, 68803

Site Contact

Stefano Tarantolo, Site 140

Clinical.Trials@bms.com

402-334-4773

Grand Island, Nebraska

Status

Recruiting

Address

"Regional" - Oncology Hematology West, PC dba Nebraska Cancer Specialist

Grand Island, Nebraska, 68803

Site Contact

Stefano Tarantolo, Site 141

Clinical.Trials@bms.com

402-334-4773

Omaha, Nebraska

Status

Recruiting

Address

"Methodist"- Oncology Hematology West, PC dba Nebraska Cancer Specialist

Omaha, Nebraska, 68114

Site Contact

Stefano Tarantolo, Site 137

Clinical.Trials@bms.com

402-334-4773

Omaha, Nebraska

Status

Recruiting

Address

"Bergan"- Oncology Hematology West, PC dba Nebraska Cancer Specialist

Omaha, Nebraska, 68124

Site Contact

Stefano Tarantolo, Site 138

Clinical.Trials@bms.com

402-334-4773

Nebraska Cancer Specialists, Omaha, Nebraska

Status

Recruiting

Address

Nebraska Cancer Specialists

Omaha, Nebraska, 68130

Site Contact

Stefano Tarantolo, Site 131

Clinical.Trials@bms.com

402-334-4773

Papillion, Nebraska

Status

Recruiting

Address

"Papillion"- Oncology Hematology West, PC dba Nebraska Cancer Specialist

Papillion, Nebraska, 68046

Site Contact

Stefano Tarantolo, Site 139

Clinical.Trials@bms.com

402-334-4773

Local Institution - 756, Cherry Hill, New Jersey

Status

Recruiting

Address

Local Institution - 756

Cherry Hill, New Jersey, 08003

Site Contact

Site 756

Clinical.Trials@bms.com

855-907-3286

Hackensack University Medical Center, Hackensack, New Jersey

Status

Recruiting

Address

Hackensack University Medical Center

Hackensack, New Jersey, 07601

Site Contact

David Siegel, Site 108

Clinical.Trials@bms.com

201-996-5900

Mount Sinai Brooklyn, Brooklyn, New York

Status

Withdrawn

Address

Mount Sinai Brooklyn

Brooklyn, New York, 11234

NYU Winthrop Hospital, Mineola, New York

Status

Recruiting

Address

NYU Winthrop Hospital

Mineola, New York, 11501

Site Contact

Marc Braunstein, Site 122

Clinical.Trials@bms.com

5166639500ext4606

New York, New York

Status

Withdrawn

Address

The Blavatnik Family- Chelsea Medical Center at Mount Sinai

New York, New York, 10011

New York University School Of Medicine, New York, New York

Status

Recruiting

Address

New York University School Of Medicine

New York, New York, 10016

Site Contact

David Kaminetzky, Site 121

Clinical.Trials@bms.com

855-907-3286

New York, New York

Status

Recruiting

Address

Icahn School of Medicine at Mount Sinai Medical Center

New York, New York, 10029

Site Contact

Sundar Jagannath, Site 109

Clinical.Trials@bms.com

212-241-7873

New York, New York

Status

Recruiting

Address

New York Presbyterian Hospital Weil Cornell Medical College

New York, New York, 10065

Site Contact

Ruben Niesvizky, Site 111

Clinical.Trials@bms.com

646-258-0156

University of Rochester Cancer Center, Rochester, New York

Status

Recruiting

Address

University of Rochester Cancer Center

Rochester, New York, 14642

Site Contact

Brea Lipe, Site 125

Clinical.Trials@bms.com

585-276-5555

Levine Cancer Institute, Charlotte, North Carolina

Status

Recruiting

Address

Levine Cancer Institute

Charlotte, North Carolina, 28204

Site Contact

Manisha Bhutani, Site 112

Clinical.Trials@bms.com

855-907-3286

Cleveland Clinic Foundation, Cleveland, Ohio

Status

Recruiting

Address

Cleveland Clinic Foundation

Cleveland, Ohio, 44195

Site Contact

Faiz Anwer, Site 117

Clinical.Trials@bms.com

520-694-8900

Columbus, Ohio

Status

Recruiting

Address

The Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210

Site Contact

Abdullah Khan, Site 124

Clinical.Trials@bms.com

614-293-6295

Local Institution - 116, Philadelphia, Pennsylvania

Status

Completed

Address

Local Institution - 116

Philadelphia, Pennsylvania, 19104

Local Institution - 123, Greenville, South Carolina

Status

Completed

Address

Local Institution - 123

Greenville, South Carolina, 29605

Baptist Cancer Center, Memphis, Tennessee

Status

Recruiting

Address

Baptist Cancer Center

Memphis, Tennessee, 38120

Site Contact

Muhammad Raza, Site 134

Clinical.Trials@bms.com

000-000-0000

Local Institution - 118, Dallas, Texas

Status

Completed

Address

Local Institution - 118

Dallas, Texas, 75390

Salt Lake City, Utah

Status

Recruiting

Address

Huntsman Cancer Institute at the University of Utah

Salt Lake City, Utah, 84112-5550

Site Contact

Brian McClune, Site 119

Clinical.Trials@bms.com

612-625-7101

Northwest Medical Specialties PLLC, Bonney Lake, Washington

Status

Withdrawn

Address

Northwest Medical Specialties PLLC

Bonney Lake, Washington, 98391

Northwest Medical Specialties PLLC, Federal Way, Washington

Status

Withdrawn

Address

Northwest Medical Specialties PLLC

Federal Way, Washington, 98003

Northwest Medical Specialties PLLC, Gig Harbor, Washington

Status

Withdrawn

Address

Northwest Medical Specialties PLLC

Gig Harbor, Washington, 98332

Northwest Medical Specialties PLLC, Puyallup, Washington

Status

Withdrawn

Address

Northwest Medical Specialties PLLC

Puyallup, Washington, 98373

Seattle, Washington

Status

Not yet recruiting

Address

University of Washington-Seattle Cancer Care Alliance

Seattle, Washington, 98109

Site Contact

Andrew Cowan, Site 126

Clinical.Trials@bms.com

855-907-3286

Northwest Medical Specialties PLLC, Tacoma, Washington

Status

Recruiting

Address

Northwest Medical Specialties PLLC

Tacoma, Washington, 98405

Site Contact

Jorge Chaves, Site 132

Clinical.Trials@bms.com

253-428-8750

International Sites

Local Institution - 853, Westmead, New South Wales, Australia

Status

Withdrawn

Address

Local Institution - 853

Westmead, New South Wales, 2145

Local Institution - 854, Adelaide, South Australia, Australia

Status

Recruiting

Address

Local Institution - 854

Adelaide, South Australia, 5000

Site Contact

Site 854

Clinical.Trials@bms.com

855-907-3286

Local Institution - 852, Box Hill, Victoria, Australia

Status

Recruiting

Address

Local Institution - 852

Box Hill, Victoria, 3128

Site Contact

Site 852

Clinical.Trials@bms.com

855-907-3286

Local Institution - 904, Calgary, Alberta, Canada

Status

Recruiting

Address

Local Institution - 904

Calgary, Alberta, T2N 4N2

Site Contact

Site 904

Clinical.Trials@bms.com

855-907-3286

Local Institution - 901, Vancouver, British Columbia, Canada

Status

Recruiting

Address

Local Institution - 901

Vancouver, British Columbia, V5Z 1M9

Site Contact

Site 901

Clinical.Trials@bms.com

855-907-3286

Local Institution - 902, Halifax, Nova Scotia, Canada

Status

Recruiting

Address

Local Institution - 902

Halifax, Nova Scotia, B3H 1V7

Site Contact

Site 902

Clinical.Trials@bms.com

855-907-3286

Local Institution - 903, Montreal, Quebec, Canada

Status

Recruiting

Address

Local Institution - 903

Montreal, Quebec, H4A 3J1

Site Contact

Site 903

Clinical.Trials@bms.com

855-907-3286

Local Institution - 704, Lile Cedax, France

Status

Recruiting

Address

Local Institution - 704

Lile Cedax, , 59037

Site Contact

Site 704

Clinical.Trials@bms.com

855-907-3286

Local Institution - 701, Pessac, France

Status

Recruiting

Address

Local Institution - 701

Pessac, , 33604

Site Contact

Site 701

Clinical.Trials@bms.com

855-907-3286

Local Institution - 703, Pierre Benite cedex, France

Status

Recruiting

Address

Local Institution - 703

Pierre Benite cedex, , 69495

Site Contact

Site 703

Clinical.Trials@bms.com

855-907-3286

Local Institution - 702, Poitiers Cedex, France

Status

Completed

Address

Local Institution - 702

Poitiers Cedex, , 86021

Local Institution - 605, Dresden, Germany

Status

Recruiting

Address

Local Institution - 605

Dresden, , 01307

Site Contact

Site 605

Clinical.Trials@bms.com

855-907-3286

Local Institution - 603, Dusseldorf, Germany

Status

Recruiting

Address

Local Institution - 603

Dusseldorf, , 40225

Site Contact

Site 603

Clinical.Trials@bms.com

855-907-3286

Local Institution - 604, Hamburg, Germany

Status

Recruiting

Address

Local Institution - 604

Hamburg, , 20246

Site Contact

Site 604

Clinical.Trials@bms.com

855-907-3286

Local Institution - 602, Heidelberg, Germany

Status

Recruiting

Address

Local Institution - 602

Heidelberg, , 69120

Site Contact

Site 602

Clinical.Trials@bms.com

855-907-3286

Local Institution - 601, Tuebingen, Germany

Status

Recruiting

Address

Local Institution - 601

Tuebingen, , 72076

Site Contact

Site 601

Clinical.Trials@bms.com

855-907-3286

Local Institution - 606, Wuerzburg, Germany

Status

Recruiting

Address

Local Institution - 606

Wuerzburg, , 97080

Site Contact

Site 606

Clinical.Trials@bms.com

855-907-3286

Local Institution - 751, Jerusalem, Yerushalayim, Israel

Status

Recruiting

Address

Local Institution - 751

Jerusalem, Yerushalayim, 91031

Site Contact

Site 751

Clinical.Trials@bms.com

855-907-3286

Local Institution - 753, Afula, Israel

Status

Withdrawn

Address

Local Institution - 753

Afula, , 1834111

Local Institution - 752, Haifa, Israel

Status

Withdrawn

Address

Local Institution - 752

Haifa, , 3109601

Local Institution - 0905, Jerusalem, Israel

Status

Withdrawn

Address

Local Institution - 0905

Jerusalem, , 91031

Local Institution - 757, Kfar Saba, Israel

Status

Withdrawn

Address

Local Institution - 757

Kfar Saba, , 44281

Local Institution - 754, Tel Hashomer, Israel

Status

Not yet recruiting

Address

Local Institution - 754

Tel Hashomer, , 52620

Site Contact

Site 754

Clinical.Trials@bms.com

855-907-3286

Local Institution - 755, Tel-Aviv, Israel

Status

Recruiting

Address

Local Institution - 755

Tel-Aviv, , 64239

Site Contact

Site 755

Clinical.Trials@bms.com

855-907-3286

Local Institution - 307, Meldola, Italy

Status

Recruiting

Address

Local Institution - 307

Meldola, , 47014

Site Contact

Site 307

Clinical.Trials@bms.com

855-907-3286

Local Institution - 306, Napoli, Italy

Status

Withdrawn

Address

Local Institution - 306

Napoli, , 80131

Local Institution - 305, Pavia, Italy

Status

Recruiting

Address

Local Institution - 305

Pavia, , 27100

Site Contact

Site 305

Clinical.Trials@bms.com

855-907-3286

Local Institution - 302, Reggio Emilia, Italy

Status

Recruiting

Address

Local Institution - 302

Reggio Emilia, , 42100

Site Contact

Site 302

Clinical.Trials@bms.com

855-907-3286

Local Institution - 303, Rome, Italy

Status

Recruiting

Address

Local Institution - 303

Rome, , 00161

Site Contact

Site 303

Clinical.Trials@bms.com

855-907-3286

Local Institution - 301, Torino, Italy

Status

Recruiting

Address

Local Institution - 301

Torino, , 10126

Site Contact

Site 301

Clinical.Trials@bms.com

855-907-3286

Local Institution - 808, Matsuyama, Ehime, Japan

Status

Recruiting

Address

Local Institution - 808

Matsuyama, Ehime, 790-8524

Site Contact

Site 808

Clinical.Trials@bms.com

855-907-3286

Local Institution - 805, Aomori, Japan

Status

Recruiting

Address

Local Institution - 805

Aomori, , 030-8553

Site Contact

Site 805

Clinical.Trials@bms.com

855-907-3286

Local Institution - 813, Hiroshima City, Japan

Status

Recruiting

Address

Local Institution - 813

Hiroshima City, , 730-8619

Site Contact

Site 813

Clinical.Trials@bms.com

855-907-3286

Local Institution - 812, Isehara City, Kanagawa, Japan

Status

Recruiting

Address

Local Institution - 812

Isehara City, Kanagawa, , 259-1193

Site Contact

Site 812

Clinical.Trials@bms.com

855-907-3286

Local Institution - 809, Kamogawa, Japan

Status

Recruiting

Address

Local Institution - 809

Kamogawa, , 296-8602

Site Contact

Site 809

Clinical.Trials@bms.com

855-907-3286

Local Institution - 802, Kyoto-city, Japan

Status

Completed

Address

Local Institution - 802

Kyoto-city, , 602-8566

Local Institution - 811, Nagasaki-shi, Japan

Status

Recruiting

Address

Local Institution - 811

Nagasaki-shi, , 8528511

Site Contact

Site 811

Clinical.Trials@bms.com

855-907-3286

Local Institution - 810, Nagoya, Japan

Status

Recruiting

Address

Local Institution - 810

Nagoya, , 464-8681

Site Contact

Site 810

Clinical.Trials@bms.com

855-907-3286

Local Institution - 801, Nagoya, Japan

Status

Recruiting

Address

Local Institution - 801

Nagoya, , 467-8602

Site Contact

Site 801

Clinical.Trials@bms.com

855-907-3286

Local Institution - 815, Ogaki, Japan

Status

Recruiting

Address

Local Institution - 815

Ogaki, , 503-8502

Site Contact

Site 815

Clinical.Trials@bms.com

855-907-3286

Local Institution - 804, Osaka, Japan

Status

Recruiting

Address

Local Institution - 804

Osaka, , 545-8586

Site Contact

Site 804

Clinical.Trials@bms.com

855-907-3286

Local Institution - 803, Sendai, Japan

Status

Completed

Address

Local Institution - 803

Sendai, , 980-8574

Local Institution - 806, Shinagawa-ku, Tokyo, Japan

Status

Recruiting

Address

Local Institution - 806

Shinagawa-ku, Tokyo, , 141-8625

Site Contact

Site 806

Clinical.Trials@bms.com

855-907-3286

Local Institution - 814, Sunto-gun, Japan

Status

Recruiting

Address

Local Institution - 814

Sunto-gun, , 411-8777

Site Contact

Site 814

Clinical.Trials@bms.com

855-907-3286

Local Institution - 807, Toyohashi, Japan

Status

Recruiting

Address

Local Institution - 807

Toyohashi, , 441-8570

Site Contact

Site 807

Clinical.Trials@bms.com

855-907-3286

Local Institution - 503, Amsterdam, Netherlands

Status

Recruiting

Address

Local Institution - 503

Amsterdam, , 1081 HV

Site Contact

Site 503

Clinical.Trials@bms.com

855-907-3286

Local Institution - 504, Maastrich, Netherlands

Status

Recruiting

Address

Local Institution - 504

Maastrich, , 6202 AZ

Site Contact

Site 504

Clinical.Trials@bms.com

855-907-3286

Local Institution - 501, Rotterdam, Netherlands

Status

Completed

Address

Local Institution - 501

Rotterdam, , 3075 EA

Local Institution - 502, Utrecht, Netherlands

Status

Recruiting

Address

Local Institution - 502

Utrecht, , 3584 CX

Site Contact

Site 502

Clinical.Trials@bms.com

855-907-3286

Local Institution - 404, Badalona (Barcelona), Spain

Status

Recruiting

Address

Local Institution - 404

Badalona (Barcelona), , 08916

Site Contact

Site 404

Clinical.Trials@bms.com

855-907-3286

Local Institution - 401, Barcelona, Spain

Status

Recruiting

Address

Local Institution - 401

Barcelona, , 08035

Site Contact

Site 401

Clinical.Trials@bms.com

855-907-3286

Local Institution - 405, Barcelona, Spain

Status

Recruiting

Address

Local Institution - 405

Barcelona, , 08908

Site Contact

Site 405

Clinical.Trials@bms.com

855-907-3286

Local Institution - 408, Madrid, Spain

Status

Recruiting

Address

Local Institution - 408

Madrid, , 28007

Site Contact

Site 408

Clinical.Trials@bms.com

855-907-3286

Local Institution - 407, Madrid, Spain

Status

Recruiting

Address

Local Institution - 407

Madrid, , 28034

Site Contact

Site 407

Clinical.Trials@bms.com

855-907-3286

Local Institution - 402, Pamplona, Spain

Status

Recruiting

Address

Local Institution - 402

Pamplona, , 31008

Site Contact

Site 402

Clinical.Trials@bms.com

855-907-3286

Local Institution - 406, Valencia, Spain

Status

Recruiting

Address

Local Institution - 406

Valencia, , 46017

Site Contact

Site 406

Clinical.Trials@bms.com

855-907-3286

Local Institution - 205, Birmingham, United Kingdom

Status

Completed

Address

Local Institution - 205

Birmingham, , B15 2TH

Local Institution - 202, Leeds, United Kingdom

Status

Recruiting

Address

Local Institution - 202

Leeds, , LS9 7TF

Site Contact

Site 202

Clinical.Trials@bms.com

855-907-3286

Local Institution - 204, Oxford, United Kingdom

Status

Recruiting

Address

Local Institution - 204

Oxford, , OX4 6LB

Site Contact

Site 204

Clinical.Trials@bms.com

855-907-3286

Local Institution - 201, Sutton, United Kingdom

Status

Completed

Address

Local Institution - 201

Sutton, , SM2 5NG

Local Institution - 203, Sutton, United Kingdom

Status

Recruiting

Address

Local Institution - 203

Sutton, , SM2 5PT

Site Contact

Site 203

Clinical.Trials@bms.com

855-907-3286